Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.

Melvin, Ann J; Montepiedra, Grace; Aaron, Lisa; Meyer, William A; Spiegel, Hans M; Borkowsky, William; Abzug, Mark J; Best, Brookie M; Crain, Marilyn J; Borum, Peggy R; Graham, Bobbie; Anthony, Patricia; Shin, Katherine; Siberry, George K

Melvin, Ann J; Montepiedra, Grace; Aaron, Lisa; Meyer, William A; Spiegel, Hans M; Borkowsky, William; Abzug, Mark J; Best, Brookie M; Crain, Marilyn J; Borum, Peggy R; Graham, Bobbie; Anthony, Patricia; Shin, Katherine; Siberry, George K.

Afiliação

Melvin AJ; From the *Division of Pediatric Infectious Disease, Department of Pediatrics, University of Washington and Seattle Children's Research Institute, Seattle, Washington; Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts; Quest Diagnostics, Baltimore, Maryland; §HJF-DAIDS, a Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Contractor to National Institute of Allergy and Infectious Diseases, National Institute

Pediatr Infect Dis J ; 36(1): 53-60, 2017 01.

Article em En | MEDLINE | ID: mdl-27749649

Assuntos

Fármacos Anti-HIV/efeitos adversos; Fármacos Anti-HIV/uso terapêutico; Atorvastatina/efeitos adversos; Atorvastatina/uso terapêutico; Infecções por HIV/complicações; Infecções por HIV/tratamento farmacológico; Hiperlipidemias/complicações; Adolescente; Adulto; Proteína C-Reativa/análise; Criança; Feminino; Humanos; Masculino; Adulto Jovem

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Atorvastatina / Hiperlipidemias Tipo de estudo: Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google